Posted from: Friday, October 30, 2015 - 11:01 AM - Present

Auvi-Q Recalled

October 26, 2016 –Auvi‑Q (epinephrine injection, USP) has been voluntarily recalled by Sanofi due to potential device malfunction. The products have been found to potentially have inaccurate dosage delivery.  This recall includes lot numbers 2299596 through 3037230, with expiration dates between March 2016 and December 2016.

Auvi‑Q (epinephrine injection, USP) is used to treat life‑threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions. Auvi‑Q is packaged with two active devices and one trainer device in a corrugate box. Auvi‑Q was distributed throughout the United States via wholesalers, pharmacies and hospitals. All Auvi‑Q is being recalled.

If a patient experiencing a serious allergic reaction (i.e., anaphylaxis) and does not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life‑threatening condition. As of October 26, 2015, Sanofi has received 26 reports of suspected device malfunctions in the US and Canada. None of these device malfunction reports have been confirmed. In these reports, patients have described symptoms of the underlying hypersensitivity reaction. No fatal outcomes have been reported among these cases.

Members with questions about this recall can go to the website or call 1-866-726-6340 for information on how to return their Auvi-Q devices.  Sanofi will provide reimbursement for out-of-pocket costs incurred for the purchase of new epinephrine auto-injectors with proof of purchase.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.


Last Updated Monday, October 21, 2019 - 12:08 AM.